TrialJournal of leukocyte biology2026

The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and functionally resets CD33+ myeloid-derived suppressor cells in patients with metastatic cancer: a phase 2 single-arm, open-label trial.

Carmela De Santo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.